Biological drugs have emerged as crucial therapeutic options due to their potency, specificity, and safety. While traditionally administered through injections, pulmonary delivery offers a non-invasive and effective alternative for both local and systemic treatment of various diseases. This method capitalizes on the lungs’ vast surface area and rapid absorption capabilities. However, developing inhalable biological drugs comes with challenges such as anatomical and physiological barriers. Despite these hurdles, advancements in formulation strategies and inhalation devices are paving the way for the successful delivery of biological drugs via inhalation.
The majority of biological drugs are peptide- and protein-based therapeutics, including monoclonal antibodies (mAbs), which have garnered significant attention for their clinical success. With over 25% of novel FDA-approved drugs falling under the biologics category, their application spans across genetic disorders, autoimmune diseases, cancers, and respiratory conditions. The high target binding affinity and specificity of biological drugs make them ideal candidates for a wide range of ailments. However, their large molecular size and poor oral bioavailability necessitate alternative delivery methods, such as inhalation, to enhance their therapeutic efficacy.
Inhaled biological drugs face challenges such as achieving optimal aerodynamic properties for effective lung deposition and overcoming barriers like mucociliary clearance and macrophage uptake. Strategies like structural simplification through antibody fragments, domain antibodies, and Nanobodies® have shown promise in enhancing tissue penetration and biodistribution. These modifications not only improve drug delivery but also address issues related to stability and immunogenicity. Moreover, the development of dry powder formulations for inhalation has demonstrated positive outcomes in preclinical studies, showcasing the potential of inhaled biological therapies for local and systemic disorders.
The fate of inhaled biological drugs post-deposition in the lungs depends on factors like dissolution, absorption, and permeation across the alveolar epithelium. Achieving the right balance between dissolution and absorption in the limited lung fluid volume remains a critical aspect of successful pulmonary drug delivery. Additionally, the interaction of inhaled biologics with pulmonary surfactant and their clearance through mucociliary mechanisms and alveolar macrophages play pivotal roles in determining their therapeutic efficacy. Understanding these dynamics is essential for optimizing the bioavailability and pharmacological action of inhaled biological drugs.
Strategic approaches to enhance the delivery of biological drugs via inhalation involve modifying their structure, leveraging antibody fragments and Nanobodies®, and addressing challenges related to enzymatic degradation and immunogenicity. These advancements not only improve the pharmacokinetics and pharmacodynamics of inhaled biological therapies but also offer novel treatment avenues for respiratory infections, lung cancer, asthma, and other pulmonary disorders. Through a combination of innovative formulations, targeted delivery systems, and comprehensive preclinical and clinical evaluations, the field of pulmonary delivery of biological drugs continues to evolve, offering promising solutions for enhanced patient outcomes and treatment efficacy.
- Inhalation provides a non-invasive and effective route for delivering biological drugs locally and systemically.
- Structural simplification through antibody fragments and domain antibodies enhances tissue penetration and biodistribution.
- Nanobodies® offer a promising strategy for targeting viral infections such as RSV and SARS-CoV-2.
- Overcoming challenges like enzymatic degradation, immunogenicity, and mucociliary clearance is crucial for successful pulmonary delivery of biological drugs.
Tags: drug delivery, freeze drying, secretion, cell culture, biopharma, formulation, regulatory, clinical trials, monoclonal antibodies, yeast
Read more on pmc.ncbi.nlm.nih.gov